Phase 1 FORAGER-1 trial demonstrates LOXO-435's superior safety profile with 41% objective response rate in metastatic urothelial cancer patients with FGFR3 alterations.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.